Compare Travere Therapeutics Inc. Common Stock (TVTX) vs YPF Sociedad Anonima American Depositary Shares (YPF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs YPF Sociedad Anonima American Depositary Shares — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while YPF Sociedad Anonima American Depositary Shares trades at $52.38 (market cap $20.31B). The key difference: YPF Sociedad Anonima American Depositary Shares is far larger — about 4.2× Travere Therapeutics Inc. Common Stock's market cap, and YPF Sociedad Anonima American Depositary Shares is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and YPF Sociedad Anonima American Depositary Shares for 6 Days on average.
| TVTX | YPF | |
|---|---|---|
Market Cap | $4.88B | $20.31B |
Volume | 1,668,577 | 1,015,599 |
Sector | Health | Energy |
52-Week High | $67.52 | $57.61 |
52-Week Low | $26.79 | $24.71 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $5.01B | $28.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
YPF trades at $51.79, down 0.35% on the day, with a bullish technical signal supported by moving averages. The company shows improving fundamentals with Q2 2026 earnings beating estimates and strong revenue growth from $18.3B in 2025 to $20.6B projected for 2026. Recent developments include a $24B LNG project gaining U.S. financing support and record quarterly cash flow generation.
The outlook remains positive with analyst consensus at Buy (46.7%) and a $56.67 price target representing 9.4% upside. Key risks include political uncertainty in Argentina and execution challenges for major capital projects. The stock offers value with attractive EV/EBITDA of 3.91x but faces margin pressure from high tax burdens.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About YPF Sociedad Anonima American Depositary Shares
YPF is an integrated energy company in Argentina. Its operations span oil and gas exploration and production, transportation, refining, and the marketing of petroleum products.
Read more on YPF →
